Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Forecasted to Post Q1 2025 Earnings of $3.80 Per Share

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Zacks Research boosted their Q1 2025 earnings estimates for shares of Vertex Pharmaceuticals in a research report issued on Tuesday, September 24th. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will earn $3.80 per share for the quarter, up from their prior estimate of $3.76. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($2.14) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2026 earnings at $4.17 EPS and FY2026 earnings at $17.20 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.53 earnings per share.

A number of other analysts have also weighed in on the stock. Piper Sandler raised their target price on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, August 2nd. BMO Capital Markets upped their price target on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a research report on Friday, May 31st. Wells Fargo & Company raised their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Finally, Canaccord Genuity Group boosted their price objective on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a research note on Wednesday, July 31st. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $486.36.

Vertex Pharmaceuticals Trading Down 0.1 %

VRTX opened at $462.88 on Thursday. The company has a market cap of $119.47 billion, a P/E ratio of 30.15 and a beta of 0.40. The company has a current ratio of 2.52, a quick ratio of 2.26 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $480.50 and its 200-day moving average is $453.23. Vertex Pharmaceuticals has a 1-year low of $341.85 and a 1-year high of $510.64.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Centaurus Financial Inc. increased its stake in Vertex Pharmaceuticals by 9.5% in the 2nd quarter. Centaurus Financial Inc. now owns 1,569 shares of the pharmaceutical company’s stock worth $735,000 after purchasing an additional 136 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Vertex Pharmaceuticals in the second quarter worth $11,104,000. Cim LLC boosted its position in Vertex Pharmaceuticals by 1.4% during the 2nd quarter. Cim LLC now owns 2,947 shares of the pharmaceutical company’s stock valued at $1,381,000 after buying an additional 42 shares during the period. Sanctuary Advisors LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter worth $13,768,000. Finally, Kestra Investment Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter valued at about $843,000. 90.96% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the sale, the chief marketing officer now directly owns 23,259 shares in the company, valued at $11,088,728.25. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Reshma Kewalramani sold 15,202 shares of the company’s stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $497.00, for a total value of $7,555,394.00. Following the transaction, the chief executive officer now directly owns 106,172 shares in the company, valued at $52,767,484. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the sale, the chief marketing officer now directly owns 23,259 shares of the company’s stock, valued at $11,088,728.25. The disclosure for this sale can be found here. Insiders sold a total of 31,767 shares of company stock worth $15,768,284 in the last quarter. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.